A state-of-the-art review on LSD1 and its inhibitors in breast cancer: Molecular mechanisms and therapeutic significance

Guan-Jun Yang1,2,3, Yan-Jun Liu2, Li-Jian Ding4, Fan Tao2, Ming-Hui Zhu2, Zhen-Yuan Shi2, Juan-Ming Wen2, Meng-Yao Niu2, Xiang Li2, Zhan-Song Xu2, Wan-Jia Qin2, Chen-Jie Fei1,2,3 and Jiong Chen1,2,3*

1State Key Laboratory for Managing Biotic and Chemical Threats to the Quality and Safety of Agro-products, Ningbo University, Ningbo, Zhejiang, China, 2Laboratory of Biochemistry and Molecular Biology, School of Marine Sciences, Ningbo University, Ningbo, China, 3Key Laboratory of Aquacultural Biotechnology Ministry of Education, Ningbo University, Ningbo, China, *Li Dak Sum Yip Yio Chin Kenneth Li Marine Biopharmaceutical Research Center, Department of Marine Pharmacy, College of Food and Pharmaceutical Sciences, Ningbo University, Ningbo, China

Breast cancer (BC) is a kind of malignant cancer in women, and it has become the most diagnosed cancer worldwide since 2020. Histone methylation is a common biological epigenetic modification mediating varieties of physiological and pathological processes. Lysine-specific demethylase 1 (LSD1), a first identified histone demethylase, mediates the removal of methyl groups from histones H3K4me1/2 and H3K9me1/2 and plays a crucial role in varieties of cancer progression. It is also specifically amplified in breast cancer and contributes to BC tumorogenesis and drug resistance via both demethylase and non-demethylase manners. This review will provide insight into the overview structure of LSD1, summarize its action mechanisms in BC, describe the therapeutic potential of LSD1 inhibitors in BC, and prospect the current opportunities and challenges of targeting LSD1 for BC therapy.

KEYWORDS
LSD1, histone demethylase, breast cancer, inhibitors, H3K4me1/2, H3K9me1/2

1 Introduction

Breast cancer (BC) is a kind of malignant tumour in women occurring in the breast glandular epithelial tissues, and it has become the most diagnosed cancer worldwide since 2020 (Siegel et al., 2021; Siegel et al., 2022). The incidence of BC is increasing year by year and patients are getting younger and younger, posing a serious threat to women’s health (Siegel et al., 2022). Although advances in early diagnosis and treatment of BC have partially alleviated the crisis of some BC patients, there are still a large number of patients suffering from BC due to their complex pathogenesis, insensitivity to existing drugs, and easy-to-develop drug resistance (Yang et al., 2019; Yang et al., 2021b). Therefore, there is an urgent need to find new and effective targeted therapies for this type of BC.
Lysine-specific demethylase 1 (LSD1) is a flavin-dependent lysine-specific histone demethylase first identified in 2004 and mediated transcriptional activation or repression via erasing methyl groups from H3K9me2/1 and H3K4me2/1, respectively (Figure 1) (Shi et al., 2004; Fang et al., 2020; Kim et al., 2021; Malagrabla et al., 2022; Song et al., 2022). Recently studies found that LSD1 could also remove the methyl groups from several non-histone proteins such as ERα, MTA1, HIF-1α, AGO2, HSP90, MEFD2, and STAT3 and be involved in many cancer cell events (Majello et al., 2019). LSD1 exhibits its catalytic mechanism via consuming oxidation of FAD and O2 and yielding HCHO and H2O2 in cellulo (Yang et al., 2018a). Apart from demethylase activity, LSD1 exhibits non-demethylase activity via interacting with its client proteins and is involved in physiological and pathological processes (Gu et al., 2020). LSD1 is also overexpressed in varieties of cancers and mediates their progression (Yang et al., 2018a; Fang et al., 2019; Fang et al., 2020). LSD1 is aberrantly expressed in BC and promotes proliferation and metastasis of BC cells (Liu et al., 2020a; Zhou et al., 2021a). Moreover, LSD1 also is involved in regulating resistance of chemotherapy and immunotherapy in BC (Kim et al., 2013; Boulding et al., 2018; Yang et al., 2018d; Qin et al., 2019; Verigos et al., 2019; Tu et al., 2020; Sobczak et al., 2022). Given the multifaceted functions of LSD1 in BC progression, new therapeutic strategies targeting LSD1 are constantly being developed, such as the discovery of novel LSD1 inhibitors, the development of dual-target inhibitors, and the combination therapies with chemical agents or immunomodulators (Kim et al., 2013; Boulding et al., 2018; Yang et al., 2018d; Qin et al., 2019; Verigos et al., 2019; Tu et al., 2020; Sobczak et al., 2022). Therefore, LSD1 is a potential target for BC therapy.

Herein, the structures, functions and the regulatory roles of LSD1 in tumorigenesis were introduced, the reported LSD1 inhibitors and their therapeutic mechanisms for BC treatment were summarized, and the current challenges and the potential opportunities of LSD1 inhibitors for BC therapy were prospected.

2 The overview of LSD1

2.1 The structure of LSD1

LSD1 is a FAD-dependent demethylase encoding a peptide with 852 amino acid residues. LSD1 consists of highly conserved three distinct domains: a SW13/Rac8/Moira (SWIRM) domain, a tower domain (TD), and a catalytic amine oxidase domain (AOD) (Figures 1A,B) (Forneris et al., 2008; Yang et al., 2018a). The SWIRM domain is an indispensable domain for LSD1-mediated histone modification and chromatin remodeling (Metzger et al., 2005). The TD is a special domain with two antiparallel helices, and it can bind to RCoR1 and form the CoREST complex (Pilotto et al., 2015; Marabelli et al., 2016). The AOD domain is the catalytic domain of LSD1, and it consists of two well-defined motifs: the substrate-recognition motif and the FAD-binding motif (Yang et al., 2018a). The latter is highly conserved and responsible for binding sites of some reported LSD1 inhibitors. The two motifs assemble into a big cavity containing the interface of enzyme activity centre (Forneris et al., 2008). In the active state of LSD1, the second lobe of the AOD domain could form a hydrophobic binding pocket SWIRM domain (Yoneyama et al., 2007). This binding pocket mediates LSD1 binding to histone H3 and is also chosen as the binding pocket for developing LSD1 inhibitors (Zhou et al., 2015).

2.2 The functions and regulations of LSD1

LSD1 plays heterogeneous roles via transcriptionally modulating its downstream genes in demethylase-dependent or -independent modes in varieties of cancers (Song et al., 2022; Yang...
et al., 2022). It acts as an oncogene in some cancers, while functioning as a cancer-suppressor gene in the other cancers (Yang et al., 2018a; Hu et al., 2019). In addition, LSD1 is also regulated by multiple epigenetic regulators in BC.

2.2.1 LSD1 as a transcription co-repressor

Upregulation of H3K4me2/1 often contributes to the transcriptional activation (Figure 1C). LSD1 removes methyl groups from active Histone 3 via assembling into different co-repressor complexes with several distinct proteins and shaping chromatin into a repressive conformation. For example, LSD1 was found to form a co-repressor complex with SIN3A/HDAC and maintain sensitivity to chemotherapy via reducing inhibiting several genes such as TGFβ2, CASP7, TERT, MDM2, and HIF1α in BC (Yang et al., 2018a). It also could assemble into LSD1/CoREST/BRMS1 and inhibit the metastasis of BC cells via reduced levels of Vimentin, COL5A2, INSIG2, MRPL33, SLC1A1, KLK11, and OLFML3 (Qiu et al., 2018).

2.2.2 LSD1 as a transcription co-activator

LSD1 also works as a transcriptional co-activator via demethylating H3K9me2/1 (Figure 1C). It can promote estrogen transcription in breast cancer cells through interacting with estrogen receptor (ER) (Bennesch et al., 2016). Additionally, LSD1 also regulates chromatin events such as DNA replication, heterochromatin, and imprinting propagation (Zhu et al., 2012; Yang et al., 2018a).

2.2.3 The epigenetic regulation of LSD1

The function of LSD1 has also been found to be regulated by many epigenetic components. For example, miR-708 inhibits BC proliferation and invasion via directly binding to the 3’ UTR of LSD1 and reducing its level (Ma et al., 2016). In addition, epigenetic modifications such as phosphorylation (Peng et al., 2015; Feng et al., 2016; Zhou et al., 2016), acetylation (Luo et al., 2016), methylation (Liu et al., 2020a), and ubiquitination (Wu et al., 2013; Yi et al., 2016; Zhou et al., 2016; Gong et al., 2021) also contribute to the function of LSD1 (Figure 2). PKCa can phosphorylate LSD1 at S112, activating its demethylase activity and enhancing the occupancy on E-cadherin promoter, and finally promote EMT and metastasis in BC (Feng et al., 2016). Phosphorylated modification is also found to regulate LSD1-mediated DNA damage (Peng et al., 2015). To be specific, LSD1 was di-phosphorylated at S131 and S137 by CK2 and Wip1, respectively, which promoted its interaction with RNF168 and RNF168-dependent 53BP1 ubiquitination and subsequent recruitment to the DNA damage sites. CK1α was also found to phosphorylate LSD1 at S687 and then induce S683 phosphorylation of LSD1 by nuclear GSK3β (Zhou et al., 2016). The di-phosphorylated LSD1 would be deubiquitylated by USP22 and induced stabilization itself. MOF, a lysine acetyltransferase first found acetylated histone H4 at K16 residue, also could catalyze the acetylation of LSD1 at K432, K433, and K436 and suppress LSD1-mediated EMT in epithelial cells (Luo et al., 2016). Arginine methyltransferase 4 (PRMT4) was also found to mediate deubiquitination and stabilization of LSD1 via dimethylating it at R838 and promoting its deubiquitination by USP7 (Liu et al., 2020a). Apart from USP7 and USP22, USP28 also could remove ubiquitin modifications from LSD1, maintain its stability, and thus confer stemness to BC cells (Wu et al., 2013). Recently, OTUD7B was also found to mediate deubiquitination of LSD1 at K226/277 residues, which stabilized LSD1 and promoted its assembly into co-repressor complex (Gong et al., 2021).

3 The role of LSD1 in breast cancer

3.1 Role of LSD1 in breast cancer progression

LSD1 is overexpressed in several subtypes of BC and functions as an oncogene mediating proliferation, differentiation, invasion, and metastasis of BC cells (Figure 3; Tables 1-3) (Ma et al., 2016; Feng et al., 2017; Yang et al., 2018a; Hu et al., 2019; Zhou et al., 2021a; Ji et al., 2021). When normal human mammary epithelial cells are exposed to carcinogens, their LSD1 levels would be upregulated and promote the carcinogenesis via reducing p53 expression level (Bradley et al., 2007). LSD1 exhibits its oncogenic functions via interacting with distinct ligands in different BC subtypes. As a major biomarker of ER-positive BC, ERα and its transcriptional activity are regulated by LSD1 via assembling into complex with different ligands to mediate BC proliferation (Lim et al., 2010; Pollock et al., 2012; Zhu et al., 2012; Andresen et al., 2017). For example, CAC1 antagonized LSD1-mediated ERα activation and suppressed the proliferation of BC cells (Kim et al., 2013), while ASXL2 promoted proliferation of BC cells via forming a complex ASXL2/LSD1/UTX/MLL to activate ERα activity (Park et al., 2016). In addition, LSD1 reduces tumor suppressor gene Lefty1 via interacting with β-catenin in BC cells (Yakulov et al., 2013), and suppresses BC cell growth through binding to histone deacetylases (HDACs) (Huang et al., 2012; Vasilatos et al., 2013). It also sensitizes BC cells to chemotherapy via assembling into a complex with SIN3A/HDAC and inhibits BC proliferation and metastasis via interacting with HDAC5 (Cao et al., 2017; Cao et al., 2018; Yang et al., 2018d). Further studies found that LSD1 promotes BC metastasis via H3K4me2 demethylase occupying the gene promoters of Snail and Slug and reducing their levels (Lin et al., 2010; Wu et al., 2012; Lin et al., 2014; Phillips and Kuperwasser, 2014; Bai et al., 2017). Interestingly, androgen receptor (AR) is also involved in BC metastasis via interacting with LSD1 to reduce E-cadherin and upregulate Vimentin (Feng et al., 2017).

Interestingly, LSD1 also exerts its function as a tumor suppressor gene via forming different complexes with distinct
ligand proteins (Li et al., 2017). LSD1 was also found to inhibit proliferation, invasion, and metastasis in vitro and in vivo via assembling into LSD1/NuRD complex (Wang et al., 2009; Li et al., 2017). This complex exhibits its heterogeneous tumor suppressor functions dependent of the different subunits in varieties of BC cells (Wang et al., 2009; Li et al., 2017). In MCF-7 cells, zinc-finger protein 516 (ZNF516) inhibited EGFR transcription, and thus reduced the proliferation and invasion of BC in vitro and in vivo via targeting CtBP/LSD1/CoREST complex (Li et al., 2017). Breast carcinoma metastasis suppressor 1 (BRMS1) is another gene coordinating with LSD1/NuRD complex to inhibit the metastasis of MCF7 cells (Qiu et al., 2018). In MDA-MB-231 cells, LSD1/NuRD complex suppressed BC tumorigenesis and metastasis via recruiting the homeotic protein SIX3 (Zheng et al., 2018). CC chemokine ligand 14 (CCL14) is a chemokine promoting angiogenesis in viral infection and tumor progression (Mortier et al., 2008; Li et al., 2011). KDM5B reduce CCL14 transcription to impede metastasis via targeting LSD1/NuRD complex (Li et al., 2011). In addition, in luminal BC, LSD1 suppressed invasion, migration, and metastasis BC cells via raising GATA3 and repressing TRIM37 (Hu et al., 2019).

Apart from as a subunit of many complexes mediating BC progression, the function of LSD1 was also regulated by several epigenetic enzymes in BC (Feng et al., 2016; Liu et al., 2020a; Gong et al., 2021). Feng et al. (2016) highlighted the PKCα-mediated phosphorylation of the S112 residue of LSD1 which was crucial for epithelial-mesenchymal transition (EMT) and
Liu et al. (2020a) found that PRMT4 methylated and stabilized LSD1 via promoting it and it binding to deubiquitinase USP7 in BC cells. Recently, Gong et al. (2021) revealed that OTUD7B could remove the Poly-Ub Chains of LSD1 at K226/277 residues, maintain the integrity of LSD1/CoREST/HDACs co-repressor complexes, and inhibit BC metastasis.

### 3.2 Role of LSD1 in tumor angiogenesis

Angiogenesis is a pivotal process for BC growth and metastasis (Ayoub et al., 2022). LSD1 is also involved in this process via modulating several pathways (Table 2) (Li et al., 2011; Lee et al., 2017). Li et al. (2011) found that LSD1 worked as a co-repressor and suppressed angiogenesis and metastasis of BC cells via assembling...
into a complex with KDM5B and NuRD and reducing the transcription of CCL4. Hypoxia-inducible factor alpha (HIF1α), a transcription factor promoting breast cancer angiogenesis, is also found to be regulated by LSD1/NuRD complex. To be specific, this complex demethylated HIF1α to stabilize it, and then stabilized HIF1α would upregulate the vascular endothelial growth factor (VEGF) via cooperating with CBP and metastasis-associated antigen 1, and induce angiogenesis in BC (Lee et al., 2017).

3.3 Role of LSD1 in the breast cancer microenvironment

Tumor microenvironment refers to the internal and external environment of tumor cells where they survive, grow, and metastasize (Xiao and Yu, 2021). Tumor stroma consists of several heterogeneous cells such as cancer-associated fibroblasts (CAFs) and macrophages (Mφ), which promote tumorigenesis via the secretion of varieties of chemokines, cytokines, and growth factors (Disis, 2010). While LSD1 increases CAF burden and reducing innate M1 Mφ infiltration at the primary tumor site in BC (Boulding et al., 2018). In TNBC, LSD1 also mediated CD8+ lymphocyte trafficking to the tumor microenvironment and reducing Mφ polarization toward M1-like phenotype (Qin et al., 2019; Tan et al., 2019; Shen et al., 2022).

3.4 Role of LSD1 in drug resistance of breast cancer

Drug resistance is one of the major causes that leads to distant metastasis, poor prognosis, and death of BC (Wen et al., 2020). LSD1 is widely involved in the resistance to chemotherapy (Kim et al., 2013; Boulding et al., 2018; Verigos et al., 2019; Sobczak et al., 2022), hormone therapy (Bennani-Baiti, 2012; Cortez et al., 2012; Benedetti et al., 2019; Sukocheva et al., 2020), immunotherapy (Qin et al., 2019; Tu et al., 2020), and targeted therapy (Strachowska et al., 2021; Liu et al., 2022) of BC (Table 3).

4 Targeting LSD1 for breast cancer therapy

Considering the crucial roles of LSD1 in BC progression, it has the potential as a therapeutic target for BC treatment. Currently, tens of LSD1 inhibitors have been documented with anti-BC activity with some of these having entered clinical trials. Herein, they were classified into seven subcategories based on their structural characteristics: PCPA-based LSD1 inhibitors, polyamine analogues, natural products, propargylamine derivatives, benzohydrazide derivatives, phenyl oxazole derivatives, and dual-target inhibitors.

### 4.1 PCPA-based LSD1 inhibitors

Since LSD1 and monoamine oxidases (MAOs) share high similarity in their catalytic domains, several LSD1 inhibitors have
been discovered based on reported MAO inhibitors via in silico screening and chemical structure optimizations (Yang et al., 2007; Yang et al., 2018a). Tranylcypromine hydrochloride (2-PCPA, 1), an irreversible monoamine oxidase (MAO) inhibitor with half maximal inhibitory concentration (IC_{50}) of 11.5 and 7.0 μM for MAO A and MAO B in vitro, respectively, has also exhibited inhibitory activity against LSD1 (IC_{50} = 22.3 μM) (Figure 4) via covalently binding to its FAD-binding motif (Li et al., 2017; Cao et al., 2018). Further study verified that compound 1 also inhibited migration, invasion, and metastasis of TNBC cell lines BT-549 and MDA-MB-231 cells and tumor bone metastasis in vivo. In the mechanism, 1 blocked the interaction between LSD1 and slug, and thus upregulated suppressor E-cadherin and reduced epithelial markers (Ferrari-Amorotti et al., 2014). To improve the potency, and selectivity of 2-PCPA, some 2-PCPA derivatives have been designed and synthesized based on multiple optimization strategies. GlaxoSmithKline Inc. has designed 2 PCPA-based LSD1 inhibitors 2 and 3 with IC_{50} of 1.7 μM, and 0.016 μM, respectively, (Figure 4) (Tu et al., 2020; Zhou et al., 2021b). N-alkylated 2-PCPA derivative 2, a selective and orally bioavailable for LSD1 inhibitor induced IFN-γ/TFN-α-expressing CD8 T cell infiltration into the tumors of 4T1 immunotherapy-resistant mice and sensitized to immunotherapy via a LSD1-EOMES switch. Interestingly, 2 showed much potent anti-BC activity than PD-L1 antibody (Tu et al., 2020). Compound 3 promoted the antigen presentation and enhanced the tumor-killing activity of tumor-specific cytotoxic T-cells in 4T1 mouse model (Zhou et al., 2021b). Compounds 4 and 5 (Figure 4) are two PCPA-4-hydroxytamoxifen conjugates, which released 4-hydroxytamoxifen catalyzing by LSD1 in vitro and in cellulo and exhibited anti-proliferative activity against MCF-7 cells at concentrations as low as 0.1 μM. In addition, both of the two conjugates have better in cellulo anti-proliferative activity than their parent compounds (Ota et al., 2016). NCD38 (6), a selective LSD1 inactivator optimized from PCPA with IC_{50} of 0.59 μM (Sugino et al., 2017), could reduce the stemness of TNBC cells and tumor growth in vitro (Zhou et al., 2021a). ORY-1001 (7), a PCPA derivative in phase II clinical trial for acute myelocytic leukemia, could inhibit TNBC cells and HER2-positive BC cells in distinct mechanisms (Figure 4) (Cuyàs et al., 2020b; Wang et al., 2022). Compound 7 inhibited HER2-positive BC via reducing SOX2-driven breast cancer stem cells. In the mechanism, compound 7 disturbed the assembly between LSD1 and co-repressor RCOR1/CoREST via blocking the binding between LSD1 and FAD cofactor, and thus enhanced transcriptional repression of SOX2 (Cuyàs et al., 2020). In TNBC, compound 7 suppressed the proliferation of TNBC cells via devitalizing androgen receptor (Wang et al., 2022).

4.3 Natural products

Natural products are one of the major sources in drug discovery due to their diverse chemical scaffolds and activity profiles (Fang et al., 2020; Yang et al., 2020; Yang et al., 2021a; Cheng et al., 2022b; Song et al., 2022). Many natural products and their derivatives have been found with in vitro inhibitory activity against LSD1.

Kong’s group identified six flavonoid compounds (Figure 6, 14–19) with inhibitory activity against LSD1 from Scutellaria baicalensis Georgi using countercurrent chromatography (CCC) (Han et al., 2018). Among them, compound 19 is the best LSD1 inhibitor with the in vitro IC_{50} of 2.98 μM and in cellulo IC_{50} of 17.94 μM against MDA-MB-231 cells. Isouqueretin (Figure 6, 20), a flavonoid compound with anti-BC activity extracted from Bidens bipinnata L, is an LSD1 inhibitor that inhibited proliferation of TNBC cell line MDA-MB-231 via activating mitochondrial-mediated apoptosis (Xu et al., 2019). Biochanin A (21), a dietary flavonoid from Cicer arietinum L, could inhibit the proliferation and metabolism of BC in cellulo and in vivo (Moon et al., 2008; Sehdev et al., 2009; Ren et al., 2018). Compound 21 was found to be effective and reversible with IC_{50} of 2.95 μM and it preferably suppressed LSD1 over MAO-A/B (>32 μM) (Wang et al., 2020). In gastric MGC-803 cells, Biochanin A induced the accumulation of H3K4me1/2 and inhibited cell growth moderately (IC_{50} = 6.77 μM) (Wang et al., 2020). Oleacein (Figure 5, 22), a dihydroxy-phenol found in extra virgin olive oil, is a FAD competitive LSD1 inhibitor with IC_{50} of 2.5 μM in vitro (Cuyàs et al., 2019). Compound 22 reduced the stemness of BC stem cells via blocking the interaction between LSD1 and the methylated histone H3, disintegrating the assembled co-

4.2 Polyamine analogues

Polyamine analogues, previously identified as the FAD-dependent spermine oxidase inhibitors, were also found to inhibit LSD1 demethylase activity in 2007 (Huang et al., 2007). Bisguanidine 8 and biguanide 9 exhibited demethylase inhibitory activity by over 50% at 1 μM but both of them lack selectivity among MAOs (Nowotarski et al., 2015). Four (bis)-thioureidopropylamine compounds (10–13) showed improved selectivity compared with their lead compounds 8 and 9 (Figure 5). Among them, compound 13 exhibited the best selectivity and potency with IC_{50} values of 5.0 and 4.8 μM in vitro, respectively. In fact, 13 also showed much more potent anticancer activity against MCF7 cells than 2-PCPA (Nowotarski et al., 2015). Further study showed that compounds 10–13 suppressed the proliferation of MCF-7 cells via increasing H3K4me2 levels, which significantly upregulated tumor suppressor genes p16, GATA4, HCAD, and SFRP2. The docking assay indicated that 11 could form three hydrogen bonds with residues N535 and A539, and FAD within the LSD catalytic pocket. In addition, the hydrophobic interactions between hydrophobic residues in lining the LSD1 pocket and 11 also contributed to their binding ability.
FIGURE 4
Chemical structures of PCPA-based LSD1 inhibitors in BC therapy.

FIGURE 5
Chemical structures of polyamine analogue-based LSD1 inhibitors.
repressor complex LSD1/RCOR1/CoREST, disturbing the occupation of LSD1 to the SOX2 promoter and finally reducing the SOX2 level. Capsaicin (Figure 6, 23), a bioactive compound from chili peppers with the broad spectrum of anticancer activity in various subtype of BC cells (Chou et al., 2009; Thoennissen et al., 2010; Wu et al., 2020; Chen et al., 2021), was found to act as reversible LSD1 inhibitor with an IC50 value of 0.6 μM (Jia et al., 2020). Compound 23 competitively occupied with FAD-binding sites within the catalytic pocket of LSD1, raised H3K4me1/2 levels and suppressed the proliferation and migration of BC cells.

The dried root of *Salvia miltiorrhiza* is a traditional Chinese medicine used for over 1,000 years to treat cardiovascular and cerebrovascular diseases, gynecological diseases, diabetes, and insomnia (Su et al., 2015; Jia et al., 2019; Shi et al., 2019). *S. miltiorrhiza* has also been reported to improve the survival rate of BC patients and several bioactive components (Figure 6, 24–29) mediated its pharmacological actions via multiple anticancer...
pathways (Jin et al., 2021; Mahmoud et al., 2021). For example, rosmarinic acid (24) could suppress proliferation, metastasis and angiogenesis, and sensitize BC cells to paclitaxel via NF-κB-p53 pathways (Mahmoud et al., 2021). Dihydrosisotanshinone I (25) inhibited the proliferation of BC cells via inducing their ferroptosis and apoptosis (Lin et al., 2019). Cryptotanshinone (26) inhibited migration through inactivating PKM2/β-Catenin signaling, and mediated drug resistance via reducing the oligomer formation of breast cancer resistance protein on the cell membrane, and thus blocking its efflux function (Zhou et al., 2020; Ni et al., 2021). Tanshinone I (27) inhibited the proliferation of MDA-MB-231 cells via activating the AMP-activated protein kinase mediating autophagic signaling (Zheng et al., 2020). Tanshinone IIA (28) sensitized BC cells to adriamycin via attenuates the stemness of BC cells by targeting the miR-125b/STARD13 signaling (Li et al., 2022). Recently, the six extracted monomeric compounds from roots of S. miltiorrhiza have been identified as LSD1 inhibitors with their IC50 values within the range 0.11–20.93 μM (Lin et al., 2020). Among them, salvianolic acid A (29) showed the best inhibitory activity against LSD1 (IC50 = 0.11 μM) and it demethylase-dependently inhibited the proliferation and migration of MDA-MB-231 cells with an IC50 value of 54.98 μM at 24 h against MDA-MB-231 cells.

_Coptis chinensis_, another traditional Chinese medicine widely used over 2,000 years for treatment of atherosclerosis, diabetes, and inflammation (Alami et al., 2020) has also been used to treat a varieties of cancers including BC (Wu et al., 2019), and isoquinoline alkaloids (Figure 6, 30–34) have been identified as the main anticancer active components of _C. chinensis_ with inhibitory activity against LSD1 (Yi et al., 2016). Epierberine (30) inhibited the proliferation and metastasis of BC cells via induced cell cycle arrest and induced apoptosis by regulating Wnt/β-catenin pathway (Dian et al., 2022). Jatrorrhizine (32) exhibited anti-proliferative activity via attenuating TNK/Wnt/β-catenin signaling in BC cells with IC50 values of 11.08, 17.11, and 22.14 μM against MCF-7, MDA-MB-231, and 4T1 cells, respectively (Sun et al., 2019). Berberine (27) sensitized the BC cells to chemotherapeutic agents via reducing XRCC1-mediated base excision repair (Gao et al., 2019). Palmatine (34) reduced the lung metastasis of TNBC via downregulating metastasis-associated protein 1 (MTA1) and increasing p53 level (Ativui et al., 2022). Recently, Li Z. R. et al. (2020) found that five protoberberine alkaloids (30–34) also showed the inhibitory activities against LSD1. All the IC50 values of them were as low as micromoles and highly selective to LSD1 over MAOs.

Recently, Ren et al. (2021) also identified four sesquiterpene-based LSD1 inhibitors (compounds 35–38) with their IC50 values within the range 3.97–22.22 μM from zedoary turmeric oil using CCC strategy. Compound 36 had the best inhibitory activity (IC50 = 3.95 μM) of them and also exhibited the anti-metastasis activity against MDA-MB-231 cells.

### 4.4 Propargylamine derivatives

Due to the similar structure between MAOs and LSD1, two MAOs inhibitors (Figure 7, 39 and 40) with active propargylamine group also showed a weak inhibitory activity against LSD1 in the millimolar range (Lee et al., 2006; Matos et al., 2009). To improve the potency of LSD1 inhibitor, a covalent and irreversible LSD1 inhibitor (41) was designed through combining the active propargylamine group with N-terminal 21 amino acids of LSD1 substrate H3, compound 41 selectively inhibited LSD1 demethylase activity with a Ki value of 0.107 μM (Culhane et al., 2006). Based on the structure of 41, Schmitt et al. (2013) designed and synthesized a set of with propargyl warhead (Figure 7, 42–45). Among them, compound 44 was the best LSD1 irreversible inhibitor with IC50 of 44.0 μM _in vitro_, while 43 has the best anti-proliferative activity against MCF7 cells (IC50 = 91.5 μM) for 24 h (Schmitt et al., 2013). The docking analysis of the binding mode between 42 and LSD1 showed that residues Y761 and D555 formed hydrogen bonds with the amine of N-propargylamine warhead and the amide nitrogen atom of the benzamide moiety, respectively. The aromatic substituents extensively form hydrophobic and T-shaped aromatic interactions with F558, F560, Y807, and H812.

### 4.5 Benzohydrazide derivatives

Sorna et al. (2013) identified six benzohydrazides (Figure 8, 46–51) IC50 values within 0.19–0.333 μM range based on virtual screening from a compound library containing 2,000,000 compounds and biochemical assay. Then, three compounds 53–55, with IC50 of 0.128, 0.013, and 0.014 μM, respectively, were gotten though structure-based optimization. Compound 55, the best potent LSD1 inhibitor of them, is reversible and specific for LSD1 and inhibits the proliferation and survival of seven BC cell lines with IC50 from 0.468 to 2.730 μM range, which is more potent than a known MAO inhibitor 2-PCPA. Further study showed that 55 suppressed the proliferation of BC cells via reducing Sox2 expression, promoting G1 cell cycle arrest, and inducing the expression of differentiation-related genes in demethylase-dependent manner (Zhang et al., 2013). The binding mode analysis using ICM software showed that 55 could form three H-bonding interactions with the residues G314, R350, and Y510 via its benzohydrazide scaffold.

### 4.6 Phenyl oxazole derivatives

The polyamine/guanidine and methionine were often key pharmacophores for designing MAOs inhibitors. Dulla et al. designed a series of compounds (Figure 9, 56–59) with related
FIGURE 7
Structure of propargylamine-based LSD1 inhibitors.

FIGURE 8
Structure of benzohydrazide-based LSD1 inhibitors.
pharmacophores using oxazole as a linker (Dulla et al., 2013). The results showed that compounds 56–58 exhibited good in vitro inhibitory activity against LSD1 with IC$_{50}$ of 16.1, 10.1, and 9.5 μM, respectively. Interestingly, all the synthesized compounds including compound 59 showed an excellent cytotoxicity activity against MDA-MB-231 cells (IC$_{50}$ = 1.035–1.328 nM) in cellulo, which suggested these compounds have other targets contributing their anticancer activity. Docking analysis showed that the free -NH$_2$ and the oxazole nitrogen of compound 56 formed H-bonding with residues T624 and R316 of LSD1, respectively, and its oxazole ring is involved in a π-cation interaction with residue R316. In case of 57, its free -NH$_2$ formed a H-bond with S760, the sulfur atom formed H-bond with M332 and V333, and the phenyl ring interacted with W751 and Y761 residues via π-π stacking. In case of 57, its replaced guanidine group could form two H-bonds with residues E308 and R310 whereas its phenyl ring interacted with R316 via π-cation interaction.

4.7 Dual-target inhibitors and combined therapy

In BC, LSD1 and KDM6A have been found to co-express and co-localize with ER, and regulate hormone receptor signaling (Benedetti et al., 2019), suggesting that developing dual-targeting agents against the two proteins are potent strategy to improve the potency of LSD1 inhibitors. Based on this hypothesis, Altucci’s group designed four dual-KDM inhibitors (Figure 10, 60–63) targeting LSD1 and KDM6A. Among them, compound 61 exhibited the best anti-BC activity with no significant toxicity and good oral potency. In the mechanism, 61 induced cell arrest and apoptosis of hormone-positive BC in cellulo and in vivo and exhibited lower toxicity against non-cancerous cells (HaCaT) compared with clinical HDAC inhibitor Vorinostat. Additionally, it also reduced the resistance to endocrine therapies, suggesting dual-target is a feasible and potent strategy to overcome drug resistance for BC therapy.

Compound 64 was identified as a non-covalent dual LSD1/G9a inhibitor with anti-leukemia activity (Speranzini et al., 2016; Menna et al., 2022). Mai’s group optimized the structure of 64 via modifying its quinazoline core and got two non-covalent, and more potent LSD1/G9a inhibitors (Figure 10, 65 and 66). Compared to lead compound 63, compounds 65 and 66 exhibited a better inhibitory activity against LSD1 but reduced the inhibitory activity against G9a. Further study showed that 65 and 66 showed better anticancer activity against MDA-MB-231, THP-1, and MV4-11 cells without significant toxicity to non-cancer AHH-1 cells compared with epigenetic drug UNCO638, which suggested that the LSD1 antagonistic activity of LSD1/G9a inhibitors endorsed with anticancer activity (Menna et al., 2022).

LSD1 has been found to promote BC proliferation via interacting with histone deacetylases (HDACs) (Cao et al., 2017). Huang’s group found that HDAC inhibitor sulforaphane suppressed the proliferation of BC cells via blocking activity of upstream transcription factor 1 (USF1) and promoting ubiquitination degradation of LSD1, and LSD1 inhibitor significantly sensitized sulforaphane to BC in cellulo and in vivo (Cao et al., 2018), which inhibited that the combined therapy or discovery of LSD1/HDAC5 inhibitors is a potential strategy for BC treatment. Zylla et al. (2022) study found that HDAC/LSD1 inhibitor 67 (Figure 10) exhibited anti-proliferative and anti-metastatic activity against TNBC in cellulo and in vivo.

Currently, hormonal drugs and chemotherapy have been widely combined in the utilization for BC therapy in clinic. But combined strategies also showed undeniable disadvantages during clinic use. To overcome this phenomenon, Zhou’s group developed a set of dual-target inhibitors based compound 68. Among these conjugators, compound 69 has
the best in vitro and in cellulo activity with IC_{50} values of 9.67, 1.36, 1.55, and 8.79 μM against ERα, ERβ, LSD1, and MCF7, respectively (He et al., 2020). Most notably, 69 exhibited better anti-BC activity in MCF-7 cells than clinical agent 4-hydroxytamoxifen.

5 Discussion and future prospects

Mounting evidence supports that LSD1 is overexpressed in many subtypes of BC and promotes their proliferation (Pollock et al., 2012; Yang et al., 2018d; Xu et al., 2019; Wang et al., 2022), differentiation (Wu et al., 2013; Zhang et al., 2013; Li et al., 2021), metastasis (Li et al., 2011; Qiu et al., 2018; Zheng et al., 2018; Hu et al., 2019; Gong et al., 2021), and drug resistance (Bennani-Baiti, 2012; Verigos et al., 2019; Zhou et al., 2021a; Liu et al., 2022), which makes LSD1 become a promising target for BC therapy. But the detailed mechanisms of the LSD1 in BC progression are unclear and more potential anti-tumor pathways or downstream genes are yet to clarify due to the heterogeneity of varieties of BC subtypes. For example, metastasis and drug resistance are two main factors responsible for BC-caused death in clinic (Cheng et al., 2021; Cheng et al., 2022a). Although there are several reported researches on the roles of LSD1 in BC metastasis and drug resistance, the specific functions of LSD1 in these two cancer cell events are yet to be investigated. In addition, many studies showed that LSD1 functioned as an oncogene or suppressor gene in BC progression dependent on its transcriptional regulatory activity via assembling into different complexes with its client proteins. Therefore, mapping the protein-protein interactome of LSD1 is a potential strategy to further clarify its function in BC development (Yatim et al., 2012; Yang et al., 2022). Meanwhile, the exploration on the functions of LSD1 in homeostasis is also imperative to avoid the potential health risks during the development and advancement of clinical trials of LSD1 inhibitors. Moreover, most of the current studies about LSD1 functions mainly focus on its histone demethylase activity, and few works are available about the roles of non-histone substrates, epigenetic modifications, and non-enzyme activity of LSD1 in BC progression (Feng et al., 2016; Liu et al.,
Thus, it is imperative to further carry out research in these areas.

Currently, some LSD1 inhibitors have entered clinical trials to combat small lung cancer cells and acute myeloid leukemia and several of them showed encouraging results (Fang et al., 2019). But there is no LSD1 inhibitor in clinical trials for BC. Many factors contribute to this phenomenon apart from the complex etiological factor of BC. First, most of the reported LSD1 inhibitors have poor selectivity, which adds to the uncertainty of drug therapy. Second, some LSD1 inhibitors such as compounds 56–59 exhibited intracellular activity inconsistent with their inhibitory activity against demethylase activity (Dulla et al., 2013), which suggested that there are potential off-target effects and unpredictable risks of some identified LSD1 inhibitors, when they were advanced into clinical trials for BC therapy. Third, like other enzyme inhibitors (Yang et al., 2018c; Wu et al., 2018; Yang et al., 2019; Yang et al., 2021c; Yang et al., 2021d), most of the reported LSD1 inhibitors were only detected in anti-BC activity in vitro or in cellulo assays with a dearth of the studies about in vivo toxicology, pharmacokinetics, and effectiveness in animals. Finally, due to the existence of several alternative signaling and isoenzymes in BC cells, LSD1 inhibitor used alone may be not sufficient to achieve the desired therapeutic effect sometimes. To solve these dilemmas, pharmaceutical chemists and pharmacologists have proposed several strategies. Given allosteric regulation is a common characteristic for metabolic enzymes (Kremer and Lyssiotis, 2022), identifying allosteric pockets or sites and developing corresponding inhibitors is a feasible strategy for the discovery of LSD1 inhibitors. Targeting the protein–protein interaction (PPI) is also an effective method to improve the selectivity of enzymes (Yang et al., 2018a; Cheng et al., 2020; Yang et al., 2021a; Yang et al., 2021c; Yang et al., 2021d; Yang et al., 2022), blocking the interaction between LSD1 and its client proteins may be also a useful strategy to develop selective LSD1 inhibitors. Metal complexes have showed promising in vivo activity for BC treatment (Yang et al., 2018b; Cheng et al., 2022b), and Yang et al. (2017) have also identified a rhodium-based LSD1 inhibitor with in cellulo anticancer activity against prostate cancer, which suggested this kind of compound is a unique source for the discovery of potent and selective LSD1 inhibitors against BC treatment. Several drug design strategy such as computer aided drug optimization and proteolysis targeting chimera (PROTAC)-strategy have been introduced to discover lead compounds against LSD1 with better biocompatibility and in vivo potency (Liu et al., 2020b; Martin-Acosta and Xiao, 2021). Moreover, combined therapy and developing dual-target inhibitors have also been used to improve the anticancer potency and overcome drug resistance of LSD1 inhibitors (Ota et al., 2016; Cao et al., 2018; Benedetti et al., 2019; Qin et al., 2019; Verigos et al., 2019; Liu et al., 2022). Drug delivery by nanocarriers is a potent strategy to increase drug utilization rate, improve potency, and reduce toxicity and drug resistance of single agent or combined therapy (Singh and Mitragotri, 2020; Vallet-Regi et al., 2022). LSD1 has been found to exhibit its activity by promoting gastric cancer cell stemness via delivered by endogenous small extracellular vesicles in vivo (Zhao et al., 2021), and the drug delivery of LSD1 siRNA using nanocarriers has exhibited potent anticancer activities in several studies (Suzuki, 2019; Li B. et al., 2020; Jiang et al., 2021).

In a word, LSD1 plays a crucial role in BC progression and drug resistance, and its inhibition is a potential anti-BC strategy due to its efficacy in current preclinical studies. Therefore, the discovery of more specific LSD1 inhibitors is imperative to deepen our understanding of the role of LSD1 in BC tumorigenesis and verify the feasibility of targeting LSD1 as an anti-BC therapy in clinic.

Author contributions

G-JY and JC: supervision, funding acquisition, and writing—original draft preparation. Y-JL, L-JD, FT, M-HZ, and Z-YS: preparation of figures and tables. J-MW, M-YN, XL, Z-SL, W-JQ, and C-JF: investigation and validation, writing, reviewing, and editing. G-JY and JC: conception, writing, reviewing, and editing. The authors contributed to the data preparation and drafted and revised the manuscript.

Funding

This work was supported by the National Natural Science Foundation of China (31972821), the General Scientific Research Project of Education of Zhejiang Province (Y202147351), the Starting Research Fund of Ningbo University (421912073), and the State Key Laboratory for Managing Biotic and Chemical Threats to the Quality and Safety of Agro-products (2010DS700124-ZZ2008).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Targeting angiogenesis in breast cancer: Current evidence and future perspectives of histone demethylase 1 (LSD1) as a therapeutic target for breast cancer therapy. Front. Pharmacol. 14 (4). doi:10.1089/bcr3249

References

1. Yang et al. 10.3389/fphar.2022.989575

2. DOI: 10.1093/nucmov/nuw11071656

3. DOI: 10.1007/s12071-015-0811-9

4. DOI: 10.1080/10549-019-08811-9

5. DOI: 10.3390/cancers11012027

6. DOI: 10.3390/plants9020244

7. DOI: 10.1007/s12071-016-113217

8. DOI: 10.1007/s12071-017-17913-x

9. DOI: 10.3390/cancers112012207

10. DOI: 10.3390/cancers11122027

11. DOI: 10.3390/plants9020244

12. DOI: 10.3390/nu11071656

13. DOI: 10.1007/s10549-016-3959-9

14. DOI: 10.1007/s10549-016-3959-9

15. DOI: 10.1093/ncm/cbn100

16. DOI: 10.1007/s10549-017-17913-x

17. DOI: 10.1093/ncm/cbn100

18. DOI: 10.1186/s41598-017-17913-x

19. DOI: 10.1007/s10549-016-3959-9

20. DOI: 10.1080/10549-019-08811-9

21. DOI: 10.3390/nu11071656

22. DOI: 10.3390/cancers11122027

23. DOI: 10.3390/cancers11012027
Danshen improves survival of patients with breast cancer and gynecological cancer. 

Front. Pharmacol. 10, 1226. doi:10.3389/fphar.2019.01226

Lin, Y. W., Kang, T. B., and Zhou, B. P. (2014). Doxorubicin enhances SnaII-LSD1-mediated PTE1 suppression in a PARP1-dependent manner. Cell Cycle 13 (11), 1708–1716. doi:10.4161/cc.28619

Long, B. B., Liu, X. H., Han, L. L., Chen, X., Wu, X. D., Wu, J. J., et al. (2022). BRD4-directed super-enhancer organization of transcription repression programs links to chemotherapeutic efficacy in breast cancer. Proc. Natl. Acad. Sci. U. S. A. 119 (6), e2019833119. doi:10.1073/pnas.2019833119

Lin, J., Ma, J., Liu, X., Jia, L., Yi, Y., Wang, Z. P., et al. (2020). PROTACs: A novel strategy for cancer therapy. Semin. Cancer Biol. 67, 171–179. doi:10.1016/j.semcancer.2020.02.006

Jin, Z. W., Feng, J. X., Li, L. L., Lin, L. Y., J., J. F., Lin, C., et al. (2020a). Arginine methylation-dependent LSD1 stability promotes invasion and metastasis of breast cancer. EMBO Rep. 21 (2), e48597. doi:10.15252/embr.201948597

Luo, H. C., Shenoy, A. K., Li, X. H., Jin, Y., Lin, L. H., Cai, Q. S., et al. (2016). MOF acetylates the histone demethylase LSD1 to suppress epithelial-to-mesenchymal transition. Cell Rep. 15 (12), 2665–2678. doi:10.1016/j.celrep.2016.05.050

Ma, L. M., Ma, Z. G., Yang, L. Q., Zhang, P., Yi, Q. T., et al. (2016). miR-708-LSD1 axis regulates the proliferation and invasion of breast cancer cells. Cancer Med. 5 (4), 684–692. doi:10.1002/cam4.623

Mahmoud, M. A., Okda, T. M., Orman, G. A., and Abd-Alhaseeb, M. M. (2021). Rosmarinic acid suppresses inflammation, angiogenesis, and improves paclitaxel induced apoptosis in a breast cancer model via NF-κB p53-caspase-3 pathways modulation. J. Appl. Biomater. 19 (4), 202–209. doi:10.3272/jabm.2021.02.024

Majello, B., Gorini, F., Saccà, C. D., and Amenta, S. (2019). Expanding the role of the histone lysine-specific demethylase LSD1 in cancer. Cancers 11 (3), 324. doi:10.3390/cancers11030324

Malagrab, G., Yarmohammadi, M., Jawed, A., Barceló, C., and Rubio-Tomás, T. (2022). The role of LSD1 and LSD2 in cancers of the gastrointestinal system. An update. Biomolecules 12 (3), 462. doi:10.3390/biom12030462

Marabell, C., Marrocco, and Matti, A. (2016). The growing structural and functional complexity of the LSD1/KDM1A histone demethylase. Curr. Opin. Struct. Biol. 41, 135–144. doi:10.1016/j.sbi.2016.07.011

Martin-Acosta, P., and Xiao, S. S. (2021). PROTACs to address the challenges facing small molecule inhibitors. Eur. J. Med. Chem. 210, 112993. doi:10.1016/j.ejmech.2021.112993

Matos, M. J., Viña, D., Quezada, E., Picciuà, C., Delogu, G., Orfali, F., et al. (2019). A new series of 3-phenylcoumarins as potent and selective MAO-B inhibitors. Bioorg. Med. Chem. Lett. 19 (12), 3268–3270. doi:10.1016/j.bmcl.2009.04.085

Menné, M., Fiorentino, F., Marrocco, B., Lucidi, A., Tomassi, S., Cilli, D., et al. (2022). Novel non-covalent LSD1 inhibitors endowed with anticancer effects in leukemia and solid tumor cellular models. Eur. J. Med. Chem. 237, 114410. doi:10.1016/j.ejmech.2022.114410

Metger, E., Wissmann, M., Yin, N., Müller, J. M., Schneider, R., Peters, A. H. F., et al. (2005). LSD1 demethylase represses histone marks to promote androgen-receptor-dependent transcription. Nature 437 (7057), 436–439. doi:10.1038/nature04020

Moon, Y. J., Shin, B. S., An, G., and Morris, M. E. (2008). Biochanin A inhibits breast cancer tumor growth in a murine xenograft model. Pharm. Res. 25, 2158–2163. doi:10.1007/s11095-008-9583-6

Mortier, A., Van Damme, J., and Proost, P. (2008). Regulation of chemokine activity by posttranslational modification. Pharmacol. Ther. 120 (2), 197–217. doi:10.1016/j.pharmthera.2008.08.006

Ni, W., Fan, H., Zheng, X., Xu, F., Wu, Y., Li, Y., et al. (2021). Cryptotanshinone inhibits EEF1-dependent and -independent BCRP effluxer formation to reverse multidrug resistance in breast cancer. Front. Oncol. 11, 628411. doi:10.3389/fonc.2021.628411

Nowotarski, S. L., Pachaiyappan, B., Holshouser, S. L., Kutz, C., Li, Y., Huang, Y., et al. (2015). Structure–activity study for (bis)ureidopropyl- and (bis)ureidoethylated 2D nanoarchitectures for stimuli-responsive drug delivery. Biomacromolecules 16 (9), 3671–3681. doi:10.1021/acs.biomac.5b00845

Park, U. H., Kang, M. R., Kim, E. J., Kwon, Y. S., Hur, W., Yoon, S. K., et al. (2016). ASXL2 promotes proliferation of breast cancer cells by linking ERα to histone methylation. Oncogene 35 (28), 3742–3752. doi:10.1038/onc.2015.443

Peng, B., Wang, J., Hu, Y., Zhao, H. L., Hou, W. Y., Zhao, H. L., et al. (2015). Modulation of LSD1 phosphorylation by CK2/WIP1 regulates RNFL68-dependent...
Activation of LSD1 inhibitors. J. Med. Chem. 2016. Polymyxins and quinazolines are LSD1/KDM1A inhibitors with miltiorrhiza: Traditional medicinal uses, chemistry, and pharmacology. Crit. Rev. Food Sci. Nutr. 2004. Histone demethylation mediated by the nuclear amine oxidase homolog CBP/p300 bromodomain inhibitor-I-CBP112 declines transcription of the key ABC transporters and sensitizes cancer cells to chemotherapy drugs. Cancers 13 (18), 4614. doi:10.3390/cancers13184614 Su, C. Y., Ming, Q. L., Rahman, K., Han, T., and Qin, L. P. (2015). Salvia miltiorrhiza: Traditional medicinal uses, chemistry, and pharmacology. Chin. J. Nat. Med. 13 (3), 163-182. doi:10.3390/15030002-9

Sugino, N., Kawahara, M., Tatsurni, G., Kanai, A., Matsui, H., Yamamoto, R., et al. (2017). A novel LSD1 inhibitor NCD38 ameliorates MDS-related leukemia with complex karyotype by attenuating leukemia programs via activating super-enhancers. Leukemia 31 (1), 2303–2314. doi:10.1038/leu.2017.59

Sukocheva, O. A., Lukina, E., Friedemann, M., Menshchikowski, M., Hagelans, A., and Alevy, G. (2020). The crucial role of epigenetic regulation in breast cancer anti-estrogen resistance: Current findings and future perspectives. Semin. Cancer Biol. 32, 55–59. doi:10.1016/j.semcancer.2019.02.004

Sun, Y. F., Gao, X. Y., Wu, P. P., Wink, M., Li, J. H., Duan, L. L., et al. (2019). Jatrohhizine inhibits mammary carcinoma cells by targeting TNK1 mediated Wnt/β-catenin signalling and epithelial-mesenchymal transition (EMT). Phytomedicine 63, 153015. doi:10.1016/j.phymed.2019.153015

Suzuki, T. (2019). Lysine-specific histone demethylase 1 (LSD1) and their inhibitors. Chem. 2019.17-19. doi:10.1039/c9cs00735j

Tan, A. H. W., Tu, W. J., McCuaig, R., Hardy, K., Donovan, T., Tsimbaldy, S., et al. (2019). Lysine-specific histone demethylase 1A regulates macrophage polarization and checkpoint molecules in the tumor microenvironment of triple-negative breast cancer. Front. Immunol. 10, 1351. doi:10.3389/fimmu.2019.01351

Thoenissen, N. H., O’Kelly, J., Lu, D., Iwanski, G. B., Li, D. T., Abbassi, S., et al. (2010). Caspaicus causes cell-cycle arrest and apoptosis in ER-positive and-negative breast cancer cells by modulating the EGFR/HER-2 pathway. Oncogene 29 (2), 285–296. doi:10.1038/onc.2009.335

Tu, W. J., McCuaig, R. D., Tan, A. H. W., Hardy, K., Seddiki, N., Ali, S., et al. (2020). Targeting nuclear LSD1 to reprogram cancer cells and reinvigorate exhausted T cells via a novel LSD1-EOMES switch. Front. Immunol. 11, 1228. doi:10.3389/fimmu.2020.01228

Vallet Regi, M., Schmitt, F., Lexano, D., Collilla, M., and Manzano, M. (2022). Engineering mesoporous silica nanoparticles for drug delivery: Where are we after two decades? Chem. Rev. 51 (13), 5365–5451. doi:10.1021/acs.chemrev.7b00159

Vatsalas, S. N., Katz, T. A., Oesterreich, S., Wan, Y., Davidson, N. E., and Huang, Y. (2013). Crosstalk between lysine-specific demethylase 1 (LSD1) and histone deacetylases mediates antineoplastic efficacy of HDAC inhibitors in human breast cancer cells. Carcinogenesis 34 (6), 1196–1207. doi:10.1093/carcin/bg303

Verjovs, J., Karalaoids, P., Kordias, D., Papapoudou-Bai, A., Evangelou, Z., Hariss, H. V., et al. (2019). The histone demethylase LSD1/KDM1A mediates chemoresistance in breast cancer cell viability via regulation of a stem cell program. Cancers 11 (10), 1855. doi:10.3390/cancers11101855

Wang, L., Li, L. Z., Han, X. Q., Wang, X. F., Zhao, D., and Liu, J. Q. (2020). Identification and biological evaluation of natural product Biochanin A. Bioorg. Chem. 97, 103674. doi:10.1016/j.bioorg.2020.103674

Wang, T., Zhang, F. L., and Sun, F. L. (2012). ORY-1001, a KDM1A inhibitor, inhibits proliferation, and promotes apoptosis of triple negative breast cancer cells by inactivating androgen receptor. Drug Dev. Res. 83 (1), 208–216. doi:10.1002/ddr.21860

Wang, Y., Zhang, H., Chen, Y. P., Sun, Y. M., Yang, F. W., Yu, W. H., et al. (2009). LSD1 is a subunit of the NuRD complex and targets the metastasis programs in breast cancer. Cell 138 (4), 660–672. doi:10.1016/j.cell.2009.05.059

Wen, N., Lv, Q., and Du, Z. G. (2020). MicroRNAs involved in drug resistance of breast cancer by regulating autophagy. J. Zhejiang Univ. Sci. B 21 (9), 690–702. doi:10.1631/jzus.B2000076

Wu, D., Jia, H. Y., Zhang, Z. R., and Li, S. J. (2020). Caspaicus suppresses breast cancer cell viability by regulating the CDK4/PI3K/Akt/β-catenin signaling pathway. Mol. Med. Rep. 22 (6), 4868–4872. doi:10.3892/mmr.2020.11585

Wu J., Luo, Y., Deng, D. H., Su, S. Y., Li, S., Xiang, L., et al. (2019). Coptisine from Coptis chinensis exerts diverse beneficial properties: A concise review. J. Cell. Mol. Med. 23 (12), 7946–7960. doi:10.1111/jcmm.14725

Wu, K. J., Zhong, H. J., Yang, G. I., Wu, C., Huang, J. M., Li, G. D., et al. (2018). Small molecule Pnl1 inhibitor blocking NF-κB signaling in prostate cancer cells. Chem. Asian J. 13 (3), 275–279. doi:10.1002/asia.201701216

Wu, Y. D., Wang, Y. F., Yang, X. W. H., Kang, T. B., Zhao, Y. X., Wang, C., et al. (2013). The deubiquitinase USP28 stabilizes LSD1 and confers stem-cell-like traits to breast cancer cells. Cell Rep. 5 (1), 224–236. doi:10.1016/j.celrep.2013.08.030

Wu, Z. Q., Li, X. Y., Hu, C. Y., Ford, M., Kleer, C. G., and Weiss, S. J. (2012). Canonical Wnt signaling regulates Slug activity and links epithelial-mesenchymal transition with epigenetic Breast Cancer I, Early Onset (BRCA1) repression. Proc. Natl. Acad. Sci. U. S. A. 109 (41), 16654–16659. doi:10.1073/pnas.1205822109

Xiao, Y., and Yu, D. H. (2021). Tumor microenvironment as a therapeutic target in cancer. Pharmacol. Ther. 221, 107753. doi:10.1016/j.pharmthera.2020.107753

Xu, X., Peng, W. H., Liu, C. Y., Li, S. X., Lei, J. L., Wang, Z., et al. (2019). Flavone-based natural product agents as new lysine-specific demethylase 1 inhibitors.
exhibiting cytotoxicity against breast cancer cells in vitro. *Bioorg. Med. Chem.* 27 (2), 370–374. doi:10.1016/j.bmc.2018.12.013

Yuvalov, T., Raggioli, A., Franz, H., and Kemler, R. (2013). Wnt3a-dependent and -independent protein interaction networks of chromatin-bound β-catenin in mouse embryonic stem cells. *Mol. Cell. Proteomics* 12 (7), 1980–1994. doi:10.1074/mcp.M112.026914

Yang, C., Li, D., Zang, S. H., Zhang, L., Zhong, Z. F., and Zhou, Y. T. (2022). Mechanisms of carcinogenic activity triggered by lysine-specific demethylase 1A. *Front. Pharmacol.* 2804, 955218. doi:10.3389/fphar.2022.955218

Yang, C., Wang, W. H., Li, J. Y., Ma, D. L., and Leung, C. H. (2018a). Mechanisms of carcinogenic activity triggered by lysine-specific demethylase 1A. *Front. Pharmacol.* 9, 455. doi:10.3389/fphar.2018.04555

Yang, G. J., Song, Y. Q., Wang, W. H., Han, Q. B., Ma, D. L., and Leung, C. H. (2021b). An optimized BRD4 inhibitor effectively eliminates NF-kB-driven triple-negative breast cancer cells. *Bioorg. Med. Chem.* 114, 105158. doi:10.1016/j.bmc.2021.105158

Yang, G. J., Wang, W. H., Lei, P. M., Wang, S. Y., Ma, D. L., and Leung, C. H. (2020). Identification of novel selective lysine-specific demethylase 1 (LSD1) inhibitors using a pharmacophore-based virtual screening combined with docking. *Chem. Biol. Drug Des.* 85 (6), 659–671. doi:10.1111/cbdd.12461

Zhao, L. J., Chen, Y. F., Zhang, Y. T., Fan, Q. Q., Ren, H. M., Zhang, C., et al. (2021). Lysine demethylase LSD1 is delivered via small extracellular vesicles promotes gastric cancer cell stemness. *EMBO Rep.* 22, e50922. doi:10.15252/embr.202050922

Zheng, I. H., Zhang, Y., Liu, G. I., Cheng, S., Zhang, G., An, C., et al. (2020). Tanshinone I regulates autophagic signaling via the activation of AMP-activated protein kinase in cancer cells. *Anticancer Drugs* 31 (6), 601–608. doi:10.1097/CAD.0000000000001908

Zheng, Y., Zeng, Y., Qu, R. F., Liu, R. Q., Huang, W., Hou, Y. Q., et al. (2018). The homotypic protein S3X suppresses carcinogenesis and metastasis through recruiting the LSD1/NuRD(MTA3) complex. *Theranostics* 8 (4), 972–989. doi:10.7155/thno.222328

Zhou, A. D., Lin, K. Y., Zhang, S. C., Chen, Y. H., Zhang, N., Xie, J. F., et al. (2016). Nuclear GSK3β promotes tumorigenesis by phosphorylating KDM1A and inducing its deubiquitylation by USP22. *Nat. Cell Biol.* 18 (9), 954–966. doi:10.1038/nclb.2016.36

Zhou, Z. L., Van der Jeught, K., Fang, Y. Z., Yu, T., Li, Y. J., Ao, Z., et al. (2021b). KDM1A inhibition is effective in reducing stemness and treating triple negative breast cancer. *Breast Cancer Res. Treat.* 185 (2), 343–357. doi:10.1007/s10549-020-05963-1

Zhou, L. J., Liu, G. I., Meng, J. W., Zhang, Y. T., Fan, Q. Q., Ren, H. M., Zhang, C., et al. (2021). Lysine demethylase LSD1 is delivered via small extracellular vesicles promotes gastric cancer cell stemness. *EMBO Rep.* 22, e50922. doi:10.15252/embr.202050922

Zhou, C., Kang, D., Xu, Y. G., Zhang, L. Y., and Zha, X. M. (2015). Identification of a novel selective lysine-specific demethylase 1 (LSD1) inhibitor inhibiting its deubiquitylation by USP22. *Nat. Cell Biol.* 18 (9), 954–966. doi:10.1038/nclb.2016.36

Zhou, M., Venkata, P. P., Viswanadhapalli, S., Palacios, B., Alejo, S., Chen, Y. H., et al. (2021a). KDM1A inhibition is effective in reducing stemness and treating triple negative breast cancer. *Breast Cancer Res. Treat.* 185 (2), 343–357. doi:10.1007/s10549-020-05963-1

Zhou, Z. L., Van der Jeught, K., Fang, Y. Z., Yu, T., Li, Y. J., Ao, Z., et al. (2021b). KDM1A inhibition is effective in reducing stemness and treating triple negative breast cancer. *Breast Cancer Res. Treat.* 185 (2), 343–357. doi:10.1007/s10549-020-05963-1

Zhou, Z. L., Van der Jeught, K., Fang, Y. Z., Yu, T., Li, Y. J., Ao, Z., et al. (2021b). An organoid-based screen for epigenetic inhibitors that stimulate antigen presentation and potentiate T-cell-mediated cytotoxicity. *Nat. Biomed. Eng.* 5 (11), 1320–1335. doi:10.1038/s41551-021-00805-x

Zhu, Q. S., Huang, Y., Marton, L. J., Woster, P. M., Davidson, N. E., and Jr Casero, R. A. (2012). Polyamine analogs modulate gene expression by inhibiting lysine-specific demethylase 1 (LSD1) and altering chromatin structure in human breast cancer cells. *Amino Acids* 42, 887–898. doi:10.1007/s00726-011-1094-1

Zylla, J. L., Hofmann, M. M., Pleselova, S., Bhattacharya, S., Calar, K., Aferowski, Y., et al. (2022). Reduction of metastasis via epigenetic modulation in a murine model of metastatic triple negative breast cancer (TNBC). *Cancers* 14 (7), 1753. doi:10.3390/cancers14071753